AIMOVIG erenumab

Drug Class

Calcitonin gene-related peptide (CGRP) receptor antagonist

Mechanism

Erenumab is a human monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes its function to prevent migraine activation.

Approved Indication

Preventive treatment of migraine in adults.

What This Means For Patients

AIMOVIG is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2018) — Sources
• EMA — Approved (2018) — Sources
• NMPA — Approved (2023) — Sources

Pivotal Clinical Evidence

• STRIVE — Goadsby et al., N Engl J Med 2017 (NCT02456740) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig
• https://www.novartis.com/news/media-releases/novartis-announces-aimovig-approved-china-preventive-treatment-migraine